Swedish CDMO recognised for its commitment to its French operations28 Nov 2017
Recipharm's four French facilities now serve over 50 of its customers worldwide, including a number of top 20 pharma firms.
Recipharm has received the “le Prix d’Excellence 2017 - Spécial Sciences de la vie” in recognition for its commitment to its French operations. The award was presented by the Swedish Chamber of Commerce in France.
The award acknowledges examples of best practice in the Franco-Swedish business community. As part of the application process, Recipharm was assessed on its commercial success, profitability, technological innovation, quality and continued commitment to its operations in France.
Over the course of its 10-year history in France, Recipharm has increased its presence significantly and its operations in the country now account for 21% of the company’s overall sales, with 73% of those sales being exported across the globe.
Recipharm, which established its French operations in 2007, now operates four manufacturing facilities in the country, located in Fontaine-les-Dijon, Pessac, Monts and Kaysersberg. From these facilities, the CDMO provides a broad range of development and manufacturing services across areas including solid dosage formulation, sterile injectables manufacturing and blow-fill-seal capabilities to a global customer base.
Jean-François Hilaire, Executive Vice President Strategy and Global Integration at Recipharm said: “We established our French operations 10 years ago to cater for demand in Europe and offer easy market access to our customers. Since then we have acquired four sites and made substantial investments into our facilities, including an EUR 18 million investment in 2016 into our blow-fill seal capability in Kaysersberg to meet customer demand in the US, Turkey, Australia and Canada."
“Our French facilities now serve over 50 of our customers worldwide, including a number of top 20 pharma firms, and employ over 20% of our staff. We have ongoing plans to grow our operations in the country and hope to see this positive trajectory continue for many years to come.”
Thomas Eldered, CEO at Recipharm added “I am honoured that Recipharm has been acknowledged for our decade-long commitment to France. We have been very pleased with the development of our business there and I would like to thank the Swedish Chamber of Commerce in France for recognising this.”
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
India to have strongest global growth in 2019?
4 Dec 2018
Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.Read more
Catalent to expand biologics packaging capabilities
3 Dec 2018
Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.Read more
Merck successfully divests Consumer Health
2 Dec 2018
Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.Read more
Digital manufacturing is a top priority for life sciences
29 Nov 2018
Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Hikma announces injectable licensing agreement
27 Nov 2018
Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation